[Ip-health] Reminder: Webinar tomorrow (Dec, 17) - Regulating drug prices: national and global implications of Canada’s recent reforms

Marcela Vieira marcelacfvieira at gmail.com
Mon Dec 16 04:15:06 PST 2019

Dear all,
Just a quick reminder that the webinar below is taking place tomorrow,
December 17.
We hope you will be able to join us for this discussion. If you can't
attend it live, the webinar will be recorded and made available at:

*Regulating drug prices: national and global implications of Canada’s
recent reforms*

Tuesday, December 17, 4pm - 5pm CET / 10am-11am EST

To join the webinar, please register here:

Speaker: Elena Lungu, Manager of Policy Development, Patented Medicine
Prices Review Board (PMPRB), Canada

The Canadian Government has recently amended its Patented Medicine
bringing significant changes to the way in which it regulates the prices of
patented drugs. Canada’s regulatory framework was originally adopted by
Parliament in 1987 through changes to the Patent Act that sought to balance
stronger patent protection for pharmaceuticals with a mechanism to ensure
their prices remain reasonable. The Patented Medicine Prices Review Board
(PMPRB) was conceived as an independent, quasi-judicial agency to protect
consumers from excessive prices. Nevertheless, today Canada has the
third-highest medicines prices in the world, behind the United States and
Switzerland, with OECD prices generally being 19% below Canadian prices.
Three decades after, the PMPRB now has new tools and information to
consider in its price regulatory review, including i) a new basket of
comparator countries for external reference pricing; ii) consideration of
value and overall affordability of a medicine and iii) regulating at the
level of the actual prices being paid in Canada, reflective of confidential
discounts provided to payers. Canada’s Minister of Health called the reform
“the biggest step to lower drug prices in a generation”. The PMPRB’s Elena
Lungu will present the motivations for the reform, most substantive changes
in the existing regulation, and expected results once the amendments come
into force on 1 July 2020, from the perspective of the regulatory agency
charged with implementing them.

The webinar is free and open to the public and will be held in English.
Participants will be able to pose questions orally or in writing, and the
speakers will respond to a selection of these during the second half of the
event. Recordings of all webinars will be made available at the Knowledge
Portal on Innovation and Access to Medicines. After registering, you will
receive a confirmation email with additional information on how to join
the webinar using the Zoom platform.

This is part of the webinar series of the Knowledge Network for Innovation
and Access to Medicines, a project of the Global Health Centre at the
Graduate Institute, Geneva.

Related materials from the Knowledge Network on Innovation and Access to

-        Research synthesis on price controls/regulation

-        Webinar “Addressing high drug prices - what can be learned from
European policies?
presented by Sabine Vogler, Austrian Public Health Institute (GÖG)

Best regards,

Marcela Vieira
Researcher and Project Coordinator of the
Knowledge Network for Innovation and Access to Medicines

Global Health Centre, Research
Graduate Institute of International and Development Studies
marcela.vieira at graduateinstitute.ch

More information about the Ip-health mailing list